MedTrace Logo

Study of DITPA in Patients With Congestive Heart Failure

NCT00103519 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2013-03-29

No results posted yet for this study

Summary

This study will assess the safety and efficacy of DITPA relative to placebo in patients with New York Heart Association (NYHA) class III or IV congestive heart failure (CHF) who have low serum T3. DITPA is an investigational agent.

Conditions

  • Heart Failure, Congestive

Interventions

DRUG

DITPA (3,5-diiodothyropropionic acid)

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Titan Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Milton Packer, MD · UT Southwestern Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00103519 on ClinicalTrials.gov